8/13
02:22 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.